Isopropyl Alcohol side effects: what 33,603 FDA adverse event reports show
Drug class
Not stated in label
Who reports
33,603 reports · 94% serious · 17,751 with death outcome · 51% female
Used for
first aid to help prevent the risk of infection in minor cuts, scrapes, and burns.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,152 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Grip strength | 124 | 726.1 560.0–941.4ROR 728.8 · calibrated p 3e-15 ✓ | 317.1 EB05 273.0 · IC025 +6.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=124 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Ex-drug abuser | 13 | 570.9 268.4–1,214.5ROR 571.1 · calibrated p 1e-11 ✓ | 206.8 EB05 128.6 · IC025 +3.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=13 | no trial arm names this drug |
| Blood ethanol | 18 | 461.1 250.3–849.5ROR 461.4 · calibrated p 1e-11 ✓ | 206.4 EB05 138.1 · IC025 +4.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=18 | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 278 | 448.6 384.5–523.4ROR 452.3 · calibrated p 2e-13 ✓ | 255.2 EB05 231.0 · IC025 +7.3 3/3 methods agree | Lab value / disease marker | serious n=278 · ♀ 100% (drug 51%) · 97% clinician | no trial arm names this drug |
| Lupus vulgaris | 481 | 426.1 379.5–478.4ROR 432.3 · calibrated p 3e-13 ✓ | 249.6 EB05 231.4 · IC025 +7.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=481 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Postmortem blood drug level | 21 | 339.8 199.4–578.9ROR 340.0 · calibrated p 6e-11 ✓ | 183.0 EB05 126.2 · IC025 +4.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=21 | no trial arm names this drug |
| Swollen joint count | 79 | 296.2 226.5–387.3ROR 296.9 · calibrated p 2e-11 ✓ | 191.0 EB05 158.2 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=79 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 174 | 293.9 245.4–352.0ROR 295.4 · calibrated p 2e-11 ✓ | 194.9 EB05 171.8 · IC025 +6.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=174 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Alcohol interaction | 569 | 258.0 234.1–284.4ROR 262.4 · calibrated p 4e-11 ✓ | 180.9 EB05 168.8 · IC025 +7.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=505 | no trial arm names this drug |
| Deep vein thrombosis postoperative | 558 | 249.0 225.8–274.5ROR 253.1 · calibrated p 5e-11 ✓ | 176.4 EB05 164.5 · IC025 +7.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=558 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Alcohol test positive | 13 | 235.1 124.1–445.4ROR 235.2 · calibrated p 3e-9 ✓ | 136.6 EB05 85.0 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=13 | no trial arm names this drug |
| Adjustment disorder with depressed mood | 547 | 233.1 211.3–257.0ROR 236.9 · calibrated p 9e-11 ✓ | 168.3 EB05 156.8 · IC025 +7.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=547 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Victim of crime | 319 | 230.7 203.0–262.3ROR 232.9 · calibrated p 1e-10 ✓ | 166.4 EB05 151.6 · IC025 +6.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=319 · ♀ 92% (drug 51%) · 95% clinician | no trial arm names this drug |
| Swollen joint count increased | 829 | 226.5 209.3–245.1ROR 232.2 · calibrated p 1e-10 ✓ | 165.2 EB05 156.0 · IC025 +7.1 3/3 methods agree | Lab value / disease marker | serious n=829 · ♀ 100% (drug 51%) · 98% clinician | no trial arm names this drug |
| Rheumatic fever | 1,131 | 218.6 204.4–233.7ROR 226.2 · calibrated p 1e-10 ✓ | 161.1 EB05 153.4 · IC025 +7.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1,131 · ♀ 100% (drug 51%) · 95% clinician | no trial arm names this drug |
| C-reactive protein | 231 | 213.6 183.9–248.0ROR 215.0 · calibrated p 3e-10 ✓ | 156.7 EB05 140.5 · IC025 +6.7 3/3 methods agree | Lab value / disease marker | serious n=231 · ♀ 100% (drug 51%) · 98% clinician | no trial arm names this drug |
| Postmortem blood drug level abnormal | 36 | 203.1 139.3–295.9ROR 203.3 · calibrated p 1e-9 ✓ | 141.6 EB05 106.8 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=36 | no trial arm names this drug |
| Dislocation of vertebra | 534 | 197.5 179.3–217.6ROR 200.7 · calibrated p 4e-10 ✓ | 149.0 EB05 138.7 · IC025 +6.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=534 · ♀ 100% (drug 51%) · 95% clinician | no trial arm names this drug |
| Facet joint syndrome | 754 | 196.6 181.2–213.2ROR 201.1 · calibrated p 4e-10 ✓ | 148.6 EB05 140.0 · IC025 +7.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=754 · ♀ 100% (drug 51%) · 92% clinician | no trial arm names this drug |
| Chemical submission | 58 | 191.7 142.8–257.4ROR 192.0 · calibrated p 1e-9 ✓ | 139.7 EB05 112.1 · IC025 +5.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=58 · ♀ 88% (drug 51%) · 100% clinician | no trial arm names this drug |
| X-ray abnormal | 414 | 188.8 169.2–210.7ROR 191.2 · calibrated p 6e-10 ✓ | 143.7 EB05 132.5 · IC025 +6.8 3/3 methods agree | Lab value / disease marker | serious n=414 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Hepatic enzyme | 32 | 185.6 125.0–275.6ROR 185.8 · calibrated p 3e-9 ✓ | 131.7 EB05 97.7 · IC025 +4.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=32 · ♀ 100% (drug 51%) · 100% clinician | no trial arm names this drug |
| Behavioural addiction | 14 | 179.3 98.9–325.2ROR 179.4 · calibrated p 2e-8 ✓ | 117.2 EB05 74.2 · IC025 +3.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=14 | no trial arm names this drug |
| Acquired porphyria | 15 | 167.7 94.7–296.7ROR 167.8 · calibrated p 2e-8 ✓ | 113.3 EB05 72.9 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=15 | no trial arm names this drug |
| Retinitis | 338 | 158.6 140.8–178.7ROR 160.2 · calibrated p 3e-9 ✓ | 125.4 EB05 114.6 · IC025 +6.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=338 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 1,394 | 146.5 138.3–155.1ROR 152.8 · calibrated p 4e-9 ✓ | 118.3 EB05 113.2 · IC025 +6.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 72.7 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Alcohol abuse | 510 | 145.8 132.5–160.5ROR 148.1 · calibrated p 5e-9 ✓ | 117.6 EB05 109.2 · IC025 +6.6 3/3 methods agree | Reporting / coding artifact | serious n=434 · ♀ 29% (drug 51%) | no trial arm names this drug |
| Foetal alcohol syndrome | 18 | 135.0 81.0–224.8ROR 135.0 · calibrated p 7e-8 ✓ | 99.4 EB05 66.5 · IC025 +4.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=18 | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 1,232 | 131.0 123.3–139.2ROR 135.9 · calibrated p 1e-8 ✓ | 108.0 EB05 103.0 · IC025 +6.6 3/3 methods agree | Lab value / disease marker | serious PRR 66.6 · ♀ 100% (drug 51%) · 95% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 980 | 127.8 119.4–136.8ROR 131.6 · calibrated p 1e-8 ✓ | 105.8 EB05 100.3 · IC025 +6.5 3/3 methods agree | Lab value / disease marker | serious n=980 · ♀ 100% (drug 51%) · 97% clinician | no trial arm names this drug |
| Alcohol poisoning | 441 | 124.5 112.4–137.8ROR 126.1 · calibrated p 2e-8 ✓ | 103.2 EB05 95.4 · IC025 +6.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=432 | no trial arm names this drug |
| Porphyria acute | 222 | 119.6 103.6–138.1ROR 120.4 · calibrated p 3e-8 ✓ | 99.5 EB05 89.0 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=222 · ♀ 100% (drug 51%) · 95% clinician | no trial arm names this drug |
| Muscle injury | 1,293 | 116.8 110.1–123.8ROR 121.4 · calibrated p 3e-8 ✓ | 98.2 EB05 93.7 · IC025 +6.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 65.4 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Blood alcohol increased | 119 | 110.9 91.2–134.7ROR 111.2 · calibrated p 7e-8 ✓ | 92.7 EB05 79.6 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious n=114 | no trial arm names this drug |
| Helicobacter infection | 1,507 | 108.3 102.6–114.3ROR 113.3 · calibrated p 4e-8 ✓ | 92.1 EB05 88.3 · IC025 +6.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 59.9 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Folliculitis | 1,478 | 104.2 98.8–110.0ROR 109.0 · calibrated p 6e-8 ✓ | 89.2 EB05 85.4 · IC025 +6.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 64.4 · ♀ 100% (drug 51%) · 96% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 905 | 102.1 95.2–109.4ROR 104.9 · calibrated p 8e-8 ✓ | 87.5 EB05 82.9 · IC025 +6.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=903 · ♀ 100% (drug 51%) · 97% clinician | no trial arm names this drug |
| Substance use disorder | 418 | 98.2 88.6–108.8ROR 99.4 · calibrated p 1e-7 ✓ | 84.5 EB05 77.9 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=418 · ♀ 29% (drug 51%) · 93% clinician | no trial arm names this drug |
| Blood ethanol increased | 30 | 97.1 66.1–142.7ROR 97.2 · calibrated p 4e-7 ✓ | 79.9 EB05 58.6 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=30 · 100% clinician | no trial arm names this drug |
| Peripheral venous disease | 534 | 96.3 88.0–105.5ROR 97.9 · calibrated p 1e-7 ✓ | 83.2 EB05 77.4 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=534 · ♀ 100% (drug 51%) · 93% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 7,415 | 19.419.0–19.8 | signal |
| Liver injury | 2,748 | 5.75.5–5.9 | signal |
| Interstitial lung disease | 711 | 4.74.3–5.0 | signal |
| Rhabdomyolysis / myopathy | 525 | 4.13.7–4.4 | signal |
| Depression | 1,365 | 3.02.9–3.2 | signal |
| Hyperglycaemia / diabetes | 1,614 | 2.92.8–3.1 | signal |
| Dependence / withdrawal | 1,366 | 2.92.7–3.0 | signal |
| Pancreatitis | 340 | 2.62.4–2.9 | signal |
| Seizure | 668 | 2.12.0–2.3 | raised |
| Serious infection | 2,170 | 1.81.7–1.8 | raised |
| Arrhythmia / qt | 525 | 1.71.6–1.8 | raised |
| Hypoglycaemia | 252 | 1.61.5–1.9 | raised |
| Gi bleeding | 412 | 1.41.3–1.5 | raised |
| Fall / fracture | 666 | 1.11.0–1.2 | raised |
| Extrapyramidal | 155 | 0.90.8–1.1 | no difference |
| Hyponatraemia | 116 | 0.90.7–1.1 | no difference |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 6,022 | 23.2 22.7–23.7ROR 28.0 · calibrated p 4e-4 ✓ | 22.4 EB05 21.9 · IC025 +4.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 17.7 · serious PRR 14.1 · 92% clinician | no trial arm names this drug |
| Completed suicide (death by suicide) | 5,459 | 43.3 42.2–44.4ROR 51.5 · calibrated p 1e-5 ✓ | 40.5 EB05 39.6 · IC025 +5.3 3/3 methods agree | Outcome field, not a reaction | age-adj. PRR 26.3 · serious PRR 24.8 · 98% clinician | no trial arm names this drug |
| Drug abuse | 5,295 | 42.1 41.1–43.2ROR 49.8 · calibrated p 1e-5 ✓ | 39.5 EB05 38.6 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 25.9 · serious PRR 24.4 · ♀ 28% (drug 51%) · 91% clinician | no trial arm names this drug |
| Overdose | 2,038 | 5.9 5.7–6.2ROR 6.2 · calibrated p 0.136 | 5.9 EB05 5.7 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 6.2 · serious PRR 4.5 | no trial arm names this drug |
| Vomiting | 1,906 | 2.5 2.4–2.7ROR 2.6 · calibrated p 0.757 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.8 · serious PRR 2.2 · ♀ 79% (drug 51%) | no trial arm names this drug |
| Fatigue (tiredness) | 1,883 | 1.5 1.4–1.6ROR 1.5 · calibrated p 0.671 | 1.5 EB05 1.5 · IC025 +0.5 | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.0 · serious PRR 1.7 · ♀ 89% (drug 51%) | no trial arm names this drug |
| Confusional state (confusion) | 1,876 | 7.3 7.0–7.6ROR 7.7 · calibrated p 0.075 | 7.2 EB05 6.9 · IC025 +2.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 5.4 · serious PRR 5.6 · ♀ 85% (drug 51%) | no trial arm names this drug |
| Nausea | 1,871 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.648 | 1.5 EB05 1.4 · IC025 +0.5 | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.0 · serious PRR 1.6 · ♀ 84% (drug 51%) | no trial arm names this drug |
| Death | 1,820 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.534 | 1.3 EB05 1.3 · IC025 +0.3 | Outcome field, not a reaction | age-adj. PRR 2.1 · serious PRR 0.8 · 91% clinician | no trial arm names this drug |
| Pain | 1,814 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.883 | 1.8 EB05 1.8 · IC025 +0.8 | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.3 · serious PRR 1.7 · ♀ 90% (drug 51%) | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 1,688 | 1.9 1.8–2.0ROR 1.9 · calibrated p 0.894 | 1.9 EB05 1.8 · IC025 +0.8 | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.3 · serious PRR 1.5 · ♀ 87% (drug 51%) | no trial arm names this drug |
| Rash | 1,659 | 2.4 2.3–2.5ROR 2.5 · calibrated p 0.828 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 1.7 · serious PRR 3.1 · ♀ 95% (drug 51%) · 92% clinician | no trial arm names this drug |
| Drug ineffective (drug did not work) | 1,565 | 0.7 0.7–0.8ROR 0.7 · calibrated p 0.145 | 0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 1.1 · ♀ 84% (drug 51%) | no trial arm names this drug |
| Intentional overdose | 1,556 | 15.6 14.8–16.4ROR 16.3 · calibrated p 0.005 ✓ | 15.2 EB05 14.6 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 9.7 · serious PRR 9.7 | no trial arm names this drug |
| Hepatic enzyme increased | 1,551 | 14.6 13.9–15.3ROR 15.2 · calibrated p 0.007 ✓ | 14.2 EB05 13.7 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | age-adj. PRR 8.6 · serious PRR 12.5 · ♀ 97% (drug 51%) · 95% clinician | no trial arm names this drug |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Isopropyl Alcohol?
In FDA FAERS, the most frequently co-reported reaction terms for Isopropyl Alcohol are toxicity to various agents, vomiting, fatigue, confusional state, nausea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Isopropyl Alcohol have an FDA boxed warning?
No. The FDA label retrieved for Isopropyl Alcohol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Isopropyl Alcohol causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 00737139-bab8-40be-ad85-32526b5eab10, effective 20250226; matched on
openfda.generic_name.exact:"ISOPROPYL ALCOHOL") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,192 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ISOPROPYL ALCOHOL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.